Recent

% | $
Quotes you view appear here for quick access.

Response Genetics, Inc Message Board

batterupbymandm 62 posts  |  Last Activity: 4 hours ago Member since: Jul 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Yesterday at the open we gapped up a few cents however the evening before in the after hours the stock traded higher after the close. Does yesterdays open still count as a gap up ? Ryman or someone else may be able to help me with an answer.

  • The only people making money with this company are the people that work there. For years investors have been stripped of their investment value by repeated delution and failure of the management to get this company to break even. The next catalyst is always a few months away but that catalyst never seems to change the overall finances of the company. If I ran my business like this company I would be broke. They need to get it together and return equity to shareholders now, not years from now.

  • Reply to

    Manipulation galore

    by nammuang Aug 12, 2016 1:37 PM
    batterupbymandm batterupbymandm Aug 13, 2016 4:04 PM Flag

    If Otrexup sales continue to grow at the current 9% per quarter rate, break even for Otrexup should occur in Q1 2017 which is a few years later than expected. Last year we were told that a near term catalyst was injector sales increase to Ferring for 2 dosages of growth hormone. It looks like that only amounted to a 200k increase in revenue over last year from Ferring. If thats the case I would hardly call that a catalyst. They tout these products but they never seem to make any serious money from them and until that happens we will be hanging in dollar land.

  • Reply to

    Earnings out

    by foogie88 Aug 9, 2016 7:09 AM
    batterupbymandm batterupbymandm Aug 9, 2016 9:40 AM Flag

    They made it sound like the changes they put in place to impact Otrexup sales were not in place for the full second quarter and thats not true, most have been in place since 2015 with exception of the new dosages. They blame every negative number on the termination of the LEO partnership but its funny they never put enough effort into finding a partner which would have taken care of that issue for investors. Otrexup has been the one product with the potential of bringing the company to break even but they never put the effort into it that it deserves. Will Suma sales in Q4 result in profitability ? Will a QST partnership be announced in Q4 after NDA submission ?

  • Reply to

    Short interest decrease 5 Million shares

    by batterupbymandm Jul 27, 2016 9:01 PM
    batterupbymandm batterupbymandm Jul 29, 2016 11:10 AM Flag

    You are correct they need to evaluate and communicate with investors regarding progress. When I called them in mid October regarding Otrexup sales, They told me all the changes they put into place were really starting to take effect,,, that apparently was not the case according to Q1 numbers. Also, Zomacton was said to be a catalyst last summer and fall with a fall 2016 launch but we have not received any updates on how many injectors were sold etc. Dont you think that information should be shared with investors ? They talk about future catalysts but once those catalyst hit the market we are left in the dark.

  • Reply to

    Short interest decrease 5 Million shares

    by batterupbymandm Jul 27, 2016 9:01 PM
    batterupbymandm batterupbymandm Jul 28, 2016 2:34 PM Flag

    They failed to put enough effort into marketing Otrexup which could have made the company profitable by now. After LEO bailed out on the psoriasis deal Antares failed to find another partner. Psoriasis is only 10% of the total Otrexup market but its 10% we could use right now. I can remember the company saying that Otrexup would sell itself. It probably will but not to its full potential. They claimed it would be a 200 million market but we cant even currently break 20 million. We will have R & D revenue for the next few quarters and hopefully a smooth Suma launch. it will be interesting see what the Otrexup sales numbers have done for the last quarter. They claim to have put all these growth strategies in place... time will tell.

  • Reply to

    Short interest decrease 5 Million shares

    by batterupbymandm Jul 27, 2016 9:01 PM
    batterupbymandm batterupbymandm Jul 28, 2016 10:37 AM Flag

    Well said Loko. It seems odd that 5 million short shares can cover yet the SP does not move. You or I cant buy 100 shares without it jumping up a penny. ATRS never takes advantage of opportunities to share investor info such as progress on products or new opportunities. Of course right now is a quiet time so they cant say anything until earnings I believe. Teva did get approval from the FDA yesterday for the Allergen merger deal. That deal should eventually result in opportunites for Antares injector platform but maybe not. Why the low, low volume lately ? Is that because the 5 million less short shares trading the penny back and forth ? This stock has been the worst investment of my life. If I ran my business like they run this company I would be broke, pathetic at best.

  • from June 15th to July 15th. That is a huge decrease. Does the market anticipate EPI approval or something else ????

  • Reply to

    Where is everyone posting?

    by nammuang Jul 18, 2016 9:47 AM
    batterupbymandm batterupbymandm Jul 19, 2016 10:03 AM Flag

    Apcodoc, what did I say that was a lie ? the quotes I used were directly from my notes of previous earnings and investor conferences. I didnt make anything up. I have been here since this company went by the ticker AIS. I am long the stock but dissappointed with management. Teva just had a presentation last week, not sure if that was what you are referring to. They did not mention EPI

  • Reply to

    Where is everyone posting?

    by nammuang Jul 18, 2016 9:47 AM
    batterupbymandm batterupbymandm Jul 18, 2016 8:40 PM Flag

    I'm here because they have my retirement savings and I wont sell at a loss. I have to ride this out until they finally follow through and make the company profitable. 2014 was going to be the" break out year", 2015 was going to be a "very exciting year for all of us", and most recently they said "I am confident 2016 will be a very successful year". They have diluted the stock time after time, robbing shareholder value. The pipeline has potential but the only ones making money off this company in the past few years are the executives and the shorts.

  • Reply to

    Where is everyone posting?

    by nammuang Jul 18, 2016 9:47 AM
    batterupbymandm batterupbymandm Jul 18, 2016 2:51 PM Flag

    Momma always told me if I don't have anything good to say... keep it to my self. Right now I don't have anything good to say. Hoping the company will show that they are looking out for the shareholders interest. If that happens, we will have something to talk about. Maybe they would like to tell us how Otrexup sales are doing by posting it on their website so investors could see it. They tell us how they put all these changes in place to boost sales but they never show us that what they have done is working.. When I called them last October they told me all the changes they put in place were really starting to take effect but months later the sales were still flat...

  • Reply to

    Teva 8AM July13

    by nealjbinder Jul 12, 2016 11:05 PM
    batterupbymandm batterupbymandm Jul 13, 2016 8:11 AM Flag

    Unfortunately their presenter has a strong accent, its not easy to understand but I hope I can understand him when he mentions EPI...

  • batterupbymandm batterupbymandm Jul 12, 2016 6:04 PM Flag

    Smart money knows something ? They always know before we do. What's ahead ?

  • Reply to

    Someone wanted this to close below $1.

    by icantrade200 Jul 6, 2016 4:06 PM
    batterupbymandm batterupbymandm Jul 6, 2016 7:03 PM Flag

    I know it wasn't me because I wanted it to close above $4 The company needs to work on returning value to shareholders, its long overdue thats for sure. I hope they have a plan...

  • batterupbymandm batterupbymandm Jun 28, 2016 9:39 PM Flag

    Where is the weatherguy, he is the one that says he knows how to read the technicals. Weatherguy, is there Sun in the forecast ?????

  • Reply to

    1.12

    by nammuang Jun 28, 2016 7:51 PM
    batterupbymandm batterupbymandm Jun 28, 2016 8:04 PM Flag

    We are sitting pretty for a push up Nam. The RSI is 60 so we are not overbought, we could push higher and cross the 200 day, weeeeeeeeeeeeeeeee

  • Reply to

    Top 3 in the NASDAQ-Top-100-BUY-Rating-Stocks

    by thanksfather1 Jun 28, 2016 9:23 AM
    batterupbymandm batterupbymandm Jun 28, 2016 6:51 PM Flag

    Being in the top three Buy rating stocks should be an indicator that we are heading up. Technicals improving, naysayers are very quiet,,, time to move up. Nice steady upward move will force the shorts to buy in or risk losing the money they made off the short position.

  • batterupbymandm batterupbymandm Jun 27, 2016 8:38 PM Flag

    Right, Antares sells to Teva in Q2, If Teva also sells those injectors in Q2, that revenue will come to ATRS in Q3. There isnt much time left in Q2 so we would be looking for Teva to sell in Q3 and that comes to ATRS in Q4. If anyone has access to Symphony numbers it would be nice to see where Otrexup sales are trending.

  • batterupbymandm batterupbymandm Jun 27, 2016 7:26 PM Flag

    From what they said, they will sell pens to Teva in Q2 at cost until sold. There will be a 1Q delay in recording revenues.

  • Some were concerned about a cash raise but sumatriptan launch should settle those worries. Sumatriptan launch in addition to increasing development revenue during the last 3 Q's of 2016 will bring the company closer to profitability.

RGDX
0.0250.0000(0.00%)Aug 10 3:59 PMEDT